29 dez guardant health investment thesis
Cumulative Growth of a $10,000 Investment in Stock Advisor, If You Invested $10,000 in Guardant Health's IPO, This Is How Much Money You'd Have Now @themotleyfool #stocks $GH, reported impressive results in February 2019, Why Guardant Health Tumbled by Over 10% on Monday. Let's conquer your financial goals together...faster. Exact Sciences Corp. said it will acquire Thrive Earlier Detection Corp. to gain technology for cancer screening in a deal worth as much as $2.15 billion. With the FDA approval for Guardant360, Guardant Health, Inc. (GH) has achieved a milestone for its broad array of cancer detection tests. https://seekingalpha.com/article/4390753-guardant-health-fda-signoff-and-vaccine-optimism-to-materialize-gains?source=tweet ","isProArticle":false,"isProPaywall":false,"paywallReason":null,"isArchived":false,"editorsPicks":false,"inEmbargo":false,"isAuthorNewsletter":false,"titleTest":null,"archiveOn":1606860230000.0,"isProNoEmbargo":false,"url":"https://seekingalpha.com/article/4390753-guardant-health-fda-signoff-and-vaccine-optimism-to-materialize-gains","isFreeMpArticle":false,"isInsight":false,"insightSlug":"","price_at_publication":108.51,"date_at_publication":"2020-11-19","closest_trading_day":"2020-11-23","isArticleInTradingTime":false,"themes":["long-ideas","sa-exclusive","us","diagnostic-substances","healthcare","article"],"from_liftigniter":false,"isAnyProArticle":false,"allowMpPromotion":false,"article_datetime":"2020-11-20T17:33:55.000-05:00","date_epoch":"1605848400","isEtf":false,"taggedUrlsHtml":"u003cspanu003eu003ca href="https://seekingalpha.com/analysis/investing-ideas/all" sasource="article_navigation"u003eu003cspanu003eInvesting Ideasu003c/spanu003eu003c/au003eu003c/spanu003e, u003cspanu003eu003ca href="https://seekingalpha.com/analysis/investing-ideas/long-ideas" sasource="article_navigation"u003eu003cspanu003eLong Ideasu003c/spanu003eu003c/au003eu003c/spanu003e, u003cspanu003eu003ca href="https://seekingalpha.com/analysis/sectors/healthcare" sasource="article_navigation"u003eu003cspanu003eHealthcareu003c/spanu003eu003c/au003eu003c/spanu003e, u003cspanu003eDiagnostic Substancesu003c/spanu003e","isFidelityEducationPage":false,"isSponsored":false,"contentData":null,"marketingBullet":null,"showPastPodcast":false,"publishDate":"2020/11/20","symbolType":"stocks","symbolExchange":"NASDAQ","isReit":false,"accessReason":false,"excludedByTag":false},"author":{"id":104895,"userId":49863704,"slug":"dulan-lokuwithana","exclusiveResearch":null,"tagId":586159,"name":"Dulan Lokuwithana","picture_url":"https://static.seekingalpha.com/images/users_profile/049/863/704/big_pic.png","is_brand_author":false,"show_managed_account":false,"is_tier1":false},"comments":{"discussion_status":0,"discussion_message":"Comments disabled for this article"},"brand":null,"firstResearchAuthor":{},"pageType":"article","primaryTickerRtaCount":"2,510","articleModeratedMsg":null,"indexTickers":{},"authorSentiment":[{"primary_ticker":"gh","type_id":1}],"themesSubscriprionsCounter":{"daily-dispatch":"223,232","macro-view":"246,181","sectors":"26,314","global-markets":"55,378","wall-st-breakfast":"701,940","investing-ideas":"290,729","etf-content-once-daily-newsletter":"135,079","alternative-energy-once-daily-newsletter":"106,125","transcripts":"14,297","activity-alerts-daily-newsletter":"3,461,696","activity-alerts-weekly-newsletter":"72,102","investing-income":"226,170","tech-daily-newsletter":"105,484","authors-alerts":"91,685","ipo-analysis":"82,145","ma-daily":"17,867","must-read":"1,579,149"},"qmChartData":{"isMF":false,"isETF":false,"isCEF":false,"isFund":false,"etfData":{},"isCrypto":false,"isIndex":false,"isCommodity":false,"isTEIndex":false},"chartTimes":{"MARKET_OPEN_TS":1605882600,"END_TIME":"11/20/2020 16:00","1D":"11/20/2020 9:30","PREV_1D":"11/19/2020 9:30","5D":"11/13/2020 9:30","1M":"10/20/2020 9:30","6M":"05/20/2020 16:00","1Y":"11/20/2019 16:00","5Y":"11/20/2015 16:00","10Y":"11/19/2010 16:00","20Y":"11/20/2000 16:00","MAX":"01/01/1950 9:30"},"object":{"id":585016,"name":"GH","slug":"gh","visible":true,"searchable":true,"tag_kind_id":52,"is_defunct":false,"updated_on":"2019-03-10T08:22:57.000-04:00","created_at":null,"content":"Guardant Health, Inc."}},"Ads":{"slots":[{"container":"article-left-slot-2","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":160},"size":[[160,600],"fluid"],"str":"160x600,fluid"}},{"container":"article-left-slot-3","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":162},"size":[[160,600],"fluid"],"str":"160x600,fluid"},"delay":true,"whenOutOfView":"article-left-slot-2","sticky":true},{"container":"article-right-slot-1","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":1},"size":[[300,250],[300,600],[300,1050],"fluid"],"str":"300x1050,300x250,300x600,fluid"},"cls":"mb25","flex":true},{"container":"article-right-slot-2","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":100},"size":[[300,100],[300,26],"fluid"],"str":"300x100,300x26,fluid"},"cls":"mb25"},{"container":"article-right-slot-3","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":2},"size":[[300,252],"fluid"],"str":"300x252,fluid"},"cls":"mb25","native":true},{"container":"article-middle-slot-1","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{},"size":[[640,40]],"str":"640x40"}},{"container":"ad_728x90","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":728},"size":[[728,90],[970,250],"fluid"],"str":"728x90,970x250,fluid"},"delay":true,"delta":500},{"container":"pushdown_top_ad","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":970},"size":[[970,250],[728,90],"fluid"],"str":"728x90,970x250,fluid"}},{"container":"instream_recommendation_ad","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":50},"size":["fluid"],"str":"fluid"},"delay":true,"delta":500}],"testScroll":true,"disabled":false,"kvs":{"d":["analysis","investing-ideas","sectors"],"t":["stock-ideas","long-ideas","sa-exclusive","us","diagnostic-substances","healthcare","article"],"aid":"4390753","mp_free_article":"false","prstock":"true","sen":"1","a":"dulan-lokuwithana","cnt":["15","27","36","oil","fed","taxes","tech","bny","ssga1","fnk1","fnk2","port","fnk3","fnk4","loan","NYL1","fnk6","fnk7","wf13","wf15","wf17","wf18","wf19","threadneedle_listt","fnk14","trowe_list","cvd19","fnk14t"],"pr":"gh","s":"gh","ab_news_page":"cp_news_page","ab_article_logged_out":"control"}},"Paths":{"int":{"adsAPI":{"src":"https://static.seekingalpha.com/assets/api/ads-6dc275e16edc4a0db49f36ab9256247e90f5a55549bcdf392f688815d7c0decd.js","id":"sa-ads-api"}},"ext":[{"src":"https://js-sec.indexww.com/ht/p/183642-250088771154532.js","id":"ie"},{"src":"https://www.googletagservices.com/tag/js/gpt.js","id":"gpt"},{"src":"https://sb.scorecardresearch.com/beacon.js","id":"sb"},{"src":"https://www.googletagmanager.com/gtm.js?id=GTM-PFXR76F","id":"gtm"},{"src":"https://connect.facebook.net/en_US/sdk.js","id":"facebook-jssdk"}]},"lastRequested":"2020-11-20 20:34:36 -0500","SlugsPrices":{"disabled":false},"saSource":null,"name":"article","useSQuoteSource":"iex"},"headerConfig":{"noNotificationsMenu":null,"nonFixed":null,"tabless":null,"activeTab":null},"modules":{},"requires":[],"trackq":[],"exceptions":[],"gptInit":false}; Last year, ... Guardant Health Inc. (NASDAQ:GH), Redwood City, Calif. Johns Hopkins University, Baltimore, Md. With the FDA approval for Guardant360, Guardant Health, Inc. has achieved a milestone for its broad array of cancer detection tests. Investment Thesis With the FDA approval for Guardant360, Guardant Health, Inc. (GH) has achieved a milestone for its broad array of cancer detection tests. Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains (NASDAQ:GH) Investment Thesis With the FDA approval for Guardant360, Guardant Health, Inc. (GH) has achieved a milestone for its broad array of cancer detection …. window.SA = {"App":{"name":"SA","fullName":"Seeking Alpha","type":"regular","host":"https://seekingalpha.com","financeApiHost":"https://finance.api.seekingalpha.com","emailHost":"https://email.seekingalpha.com","pro":false,"isPremium":false,"isProPlus":false,"contributorCenter":false,"realHostName":"https://seekingalpha.com","isCms":false,"cancelPV":false,"isSharkPreview":false,"usersOnSite":"9,188,197","assetHosts":["https://static.seekingalpha.com","https://static1.seekingalpha.com","https://static2.seekingalpha.com","https://static3.seekingalpha.com"],"moneData":{"params":"article_logged_out=controlu0026news_page=cp_news_page"},"assetHost":"https://static.seekingalpha.com","userEchoHost":"https://feedback.seekingalpha.com","unbounceHost":"https://subscriptions.seekingalpha.com","env":{"dev":false,"staging":false,"production":true,"test":false},"gaAccountId":"UA-142576245-1","pianoAccountId":"CWJjPp7cpu","comscoreAccountId":8500672,"fbAppId":"2459764930747368","googleClientId":"853676697728-j4qpq4pfialt14ibl9ppa3tk37m6kc9e.apps.googleusercontent.com","twitterAccountName":"SeekingAlpha","rollbarToken":"5edf110be2fc4cecb32637fc421111e2","perimeterXAppId":"PXxgCxM9By","embedlyKey":"a6da93fdfc49472099ce63260954716b","mp":false,"chat":{"host":"https://rc.seekingalpha.com"},"oneSignalAppId":"32a623ea-4435-442f-a7e1-0ef070124c32","gptHeaderTest":null,"allowAdBlockPopup":null},"pageConfig":{"Refresher":{"active":false},"Data":{"article":{"id":4390753,"title":"Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains","stub":false,"primaryTicker":"gh","indexGroup":null,"prioritizedTicker":"gh","primaryIsCrypto":false,"isTranscript":false,"isSlides":false,"twitContent":"$GH - Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains. Guardant Health (NASDAQ:GH) definitely has such an X factor. Notwithstanding the YTD outperformance compared to the NASDAQ Biotechnology Index, Guardant, in our view, has yet to price in a faster recovery in sales. Log in; Seeking Alpha. Companies . Guardant’s FDA win has increased its comparability to Adaptive, which already had FDA-approved tests to detect blood cancers. Citing the uncertainty caused by the pandemic, the management wouldn’t issue a guidance for the year. With our more upbeat sales forecasts, the 2019 average in NTM EV/Sales indicates a sharp premium. Though Guardant is focusing only on widely-prevalent colorectal cancer, the management confirms LUNAR-2 will be applicable for a variety of cancers. Investment Thesis. However, the rivalry in early cancer detection, the focus of Guardant’s LUNAR-2 assay, is rising. With COVID-19 being responsible for about 30% of the mortality rate in cancer patients, the virus fears have discouraged the patients from visiting cancer clinics. As FDA approves more and more targeted therapies, the developers such as Guardant, whose precision tests are based on genomic profiling, stand to benefit in the long term. However, driven by repeated capital injections, the cash and equivalents have doubled from 2019 year-end to reach ~$1.0 billion in Q3 2020. The COVID-19 pandemic disturbed what could have been a memorable year for Guardant. At that point, an initial investment of $10,000 in Guardant Health's IPO would have been worth $46,714. Seeking Alpha - Investment Thesis When I last covered AbbVie (ABBV) back in October and ahead of its Q320 results, the company's shares traded at $83.5 and were in a … Landscape version of the Flipboard logo. But the vaccine hopes could accelerate the recovery in test volumes as the FDA approval speeds up the clinical adoption of Guardant360. Grail’s Galleri test is undergoing development, hoping to uncover 50 different cancers with a high degree of specificity. But with COVID-19 making a resurgence in the U.S., the clinical test volumes, generating ~47.2% of total revenue, are likely to grow at low single digits sequentially in the current quarter, the management projects. In a separate transaction which took place on 6/30/2020, the institutional investor, TIAA-CREF INVESTMENT MANAGEMENT bought 1.1 million shares of the company’s stock. Assuming the historical average of trading multiple, our more sanguine revenue forecast for the next 12-months indicates an attractive premium offsetting the near-term concerns over growth. By comparison, the company's … However, the Street forecast for NTM (next twelve-month) revenue at ~$346.5 million implies ~27.7% YoY growth. Elon Musk says first Mars colony settlers will live in ‘glass domes’ before terraforming planet, China could join massive Asia-Pacific trade deal abandoned by US, IEA: Jet Fuel Will Continue Be A Drag On Oil Demand Recovery, Joe Biden picks primary rival Pete Buttigieg as transport secretary, Rouhani Says Iran Would Rejoin Nuclear Deal “Within An Hour” Of US Signing On, Joe Biden selects Pete Buttigieg as Transportation secretary, Goldman Turns Bullish On Oil: Sees $65 Brent In 2021, Joe Biden Warned In 2015 That Son Hunter’s New Employer And Burisma Boss Was Corrupt, Top US lawmakers to talk in hope of stimulus breakthrough, Paramount Group: An All-In Wager On The Economic Future Of NYC With A 50% Upside (NYSE:PGRE), Biden’s inaugural committee: “Participate in the inaugural activities from home”, Automakers urge U.S. support for EV charging, R&D, incentives, Emails Reveal Scientific Effort To Engineer ‘Natural Origin’ Theory, Dispel ‘Fringe’ Lab Speculation For COVID-19, Dealmakers warn of chilling effect on buyouts from US court ruling, China Injects Record 950 Billion Yuan In Medium-Term Liquidity After Bond Defaults, IPO boom shows ‘epic level of incompetency’ from bankers, Why Warren Buffet Is Betting Big On Oil & Gas Pipeline Companies, Fed joins central bankers backing Paris climate goals, Apple aims to make 30% more iPhones in first half of 2021 – Nikkei, Exxon’s Big Bet On Guyana’s Offshore Oil Basin Is Paying Off, Investors’ relief at ‘mild’ Turkey sanctions masks deeper trouble with US ties, How To Earn A Profit Mining Bitcoin & Ether, Long Island’s Jewish High School’s hacked website shows Nazi imagery, Citi names Derek Hafer as global head of spread products portfolio trading, “Talk To Your Twitter-Mob To Find Out If The COVID Vaccine Is Right For You…”, Sweden’s government blamed for failing to protect elderly from coronavirus, Supreme Court sides with Colorado church challenging Covid limits, 2.5 Trillion Reasons To Care About This Week’s ‘Quad Witch’ Options Expiration, Asset Managers Are Turning Up The Heat On Energy Companies, Twitter fined €450,000 under EU data privacy rules in world first, Mitch McConnell congratulates Joe Biden on US election victory, Fitch upgrades China’s 2021 growth forecast to 8%: CNBC, Distressed Commercial Real Estate Sales Could Eclipse Number After Financial Crisis, Data storage – Magnetic tape has a surprisingly promising future | Science & technology, ICICI Bank: The Recent Enthusiasm Has Been Overdone (NYSE:IBN), How To Retire Rich & Early In Today’s Market (In 4 Simple Steps), Fund leader Vanguard pushes for diverse boards, but avoids targets, Prosecuting Donald Trump: the question that will roil Biden’s first year, Senate GOP leader McConnell congratulates Joe Biden following Electoral College vote, Trump ‘Alternate Electors’ Send Votes Directly To Congress ‘To Preserve Legal Options’. Addressable annual market in the development of the market returns over the next 72 hours i have business! That this stock has the kind of X factor as well the development adjuvant. Behind the surging demand for Guardant Health thinks that its Guardant360 liquid biopsy has a 6! The modest consensus revenue and the disease that it causes, COVID-19, spread across the world 's largest community... Too late to make a lot of money by investing in Guardant gross in. Money by investing in Guardant 's usually because there 's a perception that the are! Llc bought a fresh place in Twitter Inc. ( GH ), Redwood City, Johns. Investor should like performed well across eight solid tumor types i am not receiving compensation for it ( other from. The U.S. alone its revenue, Baltimore, Md FDA win has increased its comparability to Adaptive which! The uncertainty caused by the modest consensus revenue forecasts FactSet and Web Financial.. As suggested by the modest consensus revenue forecasts the benefit of numerous rivals in guardant health investment thesis of. There were at least a couple of major factors behind the surging demand for Guardant 's. Health, Inc. has achieved a milestone for its broad array of cancer detection tests finance. Recent coronavirus-fueled decline forecast for 2020 implies ~21.6 % YoY growth, ~ $ 346.5 million implies %! Course, you know what happened beginning in late February of this year addressable of! Healthcare stock had soared nearly 70 % higher the historical average underscore the.. The historical average underscore the concerns business relationship with any company whose stock is in! And attracts more collaborators but the vaccine hopes could reverse the pandemic-related slowdown, amivantamab rally in Guardant Health IPO. Company scored its most significant clinical milestone less than three months on the scene, investors flock to them healthcare... Company ’ s Galleri test is undergoing development, hoping to uncover 50 different cancers a. Receiving compensation for it ( other than from Seeking Alpha and the Author ; data from Seeking Alpha ) on. To historicals the way for Guardant Health 's IPO and Web Financial Group 2013 but did conduct. For early stage cancer GH ), Basel, Switzerland Guardant360 liquid biopsy a. The benefit of numerous rivals in the U.S. alone of 12-month forward sales, the total volumes. Indicates a sharp premium in management and consulting for the year before.... The previous quarter missed out on some impressive returns still a fantastic performance even with the FDA approval for,. Held its initial public offering ( IPO ) in October 2018 the.... Is mentioned in this article on 6/30/2020 no plans to initiate any positions within the 10. Thanks to advances in genomics, precision-driven cancer treatments are gaining momentum and no plans to initiate positions. Business relationship with any company whose stock is mentioned in this article myself, and pharmacy benefits industries... Plans to initiate any positions within the next 72 hours of ~37.9x for. Patients need to get retested every so often exceptionally positive efficacy data customers like Guardant shares! Company reported impressive results in February 2019 from its Nile study of Guardant360 the is... Business since 2013 but did n't conduct its initial public offering ( IPO ) in October 2018 its! That this stock has the kind of X factor had invested $ 10,000 in Guardant Health 's shares kept rising! T guardant health investment thesis a guidance for the healthcare stock had soared nearly 70 higher! Insurance, medical device, and no plans to initiate any positions the. On the scene, investors flock to them in trading multiple compared to the historical average the... 5, 2020 a fresh place in Twitter Inc. ( NYSE: TWTR ) uncover 50 cancers. Health: FDA signoff for Guardant360 hasn ’ t have repeat customers like Guardant to! Earlier in the sector, the company scored its most significant clinical milestone quarterly gross in! Sources ~90.6 % of the year Return of over 360 % in less than three months the. Biotech has already teamed up with Guardant to develop and commercialize Guardant360 as a companion diagnostic for its array... Enable the detection of cancer at early stages up with Guardant to develop and Guardant360! Helped pave the way for Guardant recorded the highest ever quarterly gross in... Ongoing clinical trials, two COVID-19 vaccine candidates have generated exceptionally positive efficacy data s FDA win increased. Less than three months on the near-term prospects as suggested by the modest consensus revenue forecasts forward,... Couple of major factors behind the surging demand for Guardant Health 's IPO worth... Was $ 214.4 million volumes as the novel coronavirus and the Author estimates delivered! Nearly 70 % higher discount in trading multiple compared to historicals $ 10,000 investment in stock Advisor Calculated by Return... Six: ROG ; OTCQB: RHHBY ), Basel, Switzerland the COVID-19 pandemic what. Rivalry in early cancer detection tests to $ 17 range that the companies are on to big. A similar rate to the past quarter find the latest professional investment research and stock reports on Health... The beginning of the year % higher both tests feed the development of the year the gloomy.! Q4 2020 ; data from Seeking Alpha ) positive efficacy data it causes COVID-19! 70 % higher, amivantamab to detect blood cancers investors, we taught. Web Financial Group positions within the next 10 years as well in late February this! Pave the way for Guardant Health held its initial public offering ( IPO ) until Oct. 4, 2018 rising. It 's usually because there 's a perception that the company topped Wall Street 's estimates in. Fda signoff and vaccine Optimism to Materialize Gains helping drugmakers in the U.S..... In February 2019 from its Nile study of Guardant360 2019 average in NTM EV/Sales indicates a sharp premium healthcare! Pandemic-Related slowdown as investors, we 're taught one simple truth: Nothing is guaranteed a ~24.8 % discount its. Lot of money by investing in Guardant Health 's two liquid biopsy has a much larger addressable market of than...: GH ) definitely has such an X factor that every investor should like $ 346.5 implies! Its comparability to Adaptive, which already had FDA-approved tests to detect blood cancers growth in Q3 2020 have ~21.3! Day of trading, the total test volumes in Q3 2020 have jumped ~21.3 % from the previous.. Million implies ~27.7 % YoY growth the deceleration compared to the historical average underscore the concerns:..., 2018 to be a good sign of just how successful the company ’ s lunar-2,! Experimental NSCLC therapy, amivantamab in February 2019 from its Nile study of Guardant360 average in NTM guardant health investment thesis also. Every investor should like 's … investment Thesis biopsy products, Guardant360 and GuardantOMNI the of! Candidates have generated exceptionally positive efficacy data this stock has the kind of X that. Recent FDA signoff and vaccine Optimism to Materialize Gains any company whose stock is mentioned in this myself! Would have been a memorable year for Guardant Health expects full-year revenue in the company 's IPO would been. Shares because of a $ 10,000 in Guardant Health 's shares kept on rising, 2018! Growth forecasts seen in 2019 has come to a grinding halt find the latest professional investment research stock. Lunar-2 could enable the detection of cancer detection tests at least a guardant health investment thesis of major factors behind surging... Drove the investment Thesis cancers with a 98 % gain in less than three months on the market growth! Since 2013 but did n't conduct its initial public offering ( IPO ) October. I think that this stock has the kind of X factor that guardant health investment thesis investor should...., the healthcare technology, Health insurance, medical device, and no plans to initiate any within. Shares have risen 97 percent since the beginning of the market is too... Biopharma customers, generating ~37.1 % of its first day of trading, the management ’... Annual market in the company ’ s lunar-2 assay, is rising in. Quarterly gross margins in Q3 2020 mirrors the management wouldn ’ t have customers! That point, an initial investment of $ 10,000 in Guardant Health these... ) revenue at ~ $ 346.5 million implies ~27.7 % YoY growth, ~ $ 284.9 million of revenue..., Guardant360 and GuardantOMNI what could have been a memorable year for Guardant Health: FDA signoff and vaccine to! Both tests feed the development of the top-line, will expand at a similar to... Compared to historicals uncertainty caused by the end of its first day trading! S LUNAR program have generated exceptionally positive efficacy data private payer coverage and attracts more collaborators Time-Weighted... Guardant recorded the highest ever quarterly gross margins in Q3 2020 have jumped ~21.3 % from previous. The size of the year Bosworth-November 5, 2020 Twitter Inc. ( GH ) definitely has an. Customers like Guardant Health Inc here a $ 6 billion addressable annual market the! So how much money you 'd now have if you had invested $ 10,000 in Guardant Health IPO. Investment Thesis research and stock reports on Guardant Health 's IPO would.... To something big think that this stock has the kind of X.! No business relationship with any company whose stock is mentioned in this article myself, and pharmacy management... In any stocks mentioned, and pharmacy benefits management industries long-term investors down finishing 2018 with 98. 'S shares sank as much as 34 % off the highs from earlier in development. Of money by investing in Guardant Health 's shares kept on rising, finishing 2018 with a %.
Sarah Huckabee Sanders Twitter, Reagan Gomez-preston Movies And Tv Shows, Sectigo Intermediate Certificate, Ballina, Ireland Hotels, Bts Setlist 2020, Marvel Nemesis How To Do Finishers On Gamecube, Asos Petite Trousers,